Treatment of IgE-mediated disease
AssigneesTrustees of Boston University, Boston Medical Center Corporation
InventorsLisa Ganley-Leal, John H. Connor
Life of this patent
Estimating the term…
Abstract
The methods and compositions described herein are based, in part, on the discovery of a polypeptide of soluble CD23 (sCD23) that binds and sequesters IgE. Thus, the sCD23 peptides, polypeptides and derivatives described herein are useful for treating conditions or disorders involving increased IgE levels such as e.g., allergy, anaphylaxis, inflammation, lymphoma, and certain cancers.
Claims24
A compound of the formula X1—R0 (SEQ ID NO:
- 214), wherein R0 comprises SEQ ID NO:
- 4 and X1 comprises
- TT QSLKQLEERA ARNVSQVSKN LESHHGDQMA QKSQSTQISQ ELEELRAEQQ RLKSQDLELS WNLNGLQADL SSFKSQELNE RNEASDLLER LREEVTKLRM ELQVS (SEQ ID NO:
- 7), or a contiguous fragment of at least 15 amino acids of SEQ ID NO:
- 7 wherein the compound does not bind detectably to CD21.
A compound of the formula R0—X2 (SEQ ID NO:
- 215), wherein R0 comprises SEQ ID NO:
- 4 and X2 comprises SEGSAE (SEQ ID NO:
- 9), SEGSA (SEQ ID NO:
- 10), SEGS (SEQ ID NO:
- 11), SEG, SE, S, L, or —COOH, and
- wherein the compound comprises a high affinity binding site for IgE formed by the amino acid substitution D107E of SEQ ID NO:
- 4.
A compound of the formula X1—R0—X2 (SEQ ID NO:
- 216), wherein
- R0 comprises SEQ ID NO:
- 4,
- X1 comprises at least 15 contiguous amino acids of
- TT QSLKQLEERA ARNVSQVSKN LESHHGDQMA QKSQSTQISQ ELEELRAEQQ RLKSQDLELS WNLNGLQADL SSFKSQELNE RNEASDLLER LREEVTKLRM ELQVS (SEQ ID NO:
- 7), and
- X2 comprises SEGSAE (SEQ ID NO:
- 9), SEGSA (SEQ ID NO:
- 10), SEGS (SEQ ID NO:
- 11), SEG, SE, S, L, or —COOH, and
- wherein the compound comprises a high affinity binding site for IgE formed by the amino acid substitution D107E of SEQ ID NO:
- 4.
A method for reducing a subject's immune response to an allergen, the method comprising:
- administering to a subject a pharmaceutical composition containing an effective amount of a compound selected from:
- a compound of formula X1—R0 (SEQ ID NO:
- 214), wherein R0 comprises SEQ ID NO:
- 4 and X1 comprises
- TT QSLKQLEERA ARNVSQVSKN LESHHGDQMA QKSQSTQISQ ELEELRAEQQ RLKSQDLELS WNLNGLQADL SSFKSQELNE RNEASDLLER LREEVTKLRM ELQVS (SEQ ID NO:
- 7), or a contiguous fragment of at least 15 amino acids of SEQ ID NO:
- 7 wherein the compound does not bind detectably to CD21,
- a compound of formula R0—X2 (SEQ ID NO:
- 215), wherein R0 comprises SEQ ID NO:
- 4 and X2 comprises SEGSAE (SEQ ID NO:
- 9), SEGSA (SEQ ID NO:
- 10), SEGS (SEQ ID NO:
- 11), SEG, SE, S, L, or —COOH, wherein the compound does not bind detectably to CD21, and
- a compound of formula X1—R0—X2 (SEQ ID NO:
- 216), wherein R0 comprises SEQ ID NO:
- 4, X1 comprises at least 15 contiguous amino acids of TT QSLKQLEERA ARNVSQVSKN LESHHGDQMA QKSQSTQISQ ELEELRAEQQ RLKSQDLELS WNLNGLQADL SSFKSQELNE RNEASDLLER LREEVTKLRM ELQVS (SEQ ID NO:
- 7), and X2 comprises SEGSAE (SEQ ID NO:
- 9), SEGSA (SEQ ID NO:
- 10), SEGS (SEQ ID NO:
- 11), SEG, SE, S, L, or —COOH, wherein the compound does not bind detectably to CD21;
- and a pharmaceutically acceptable carrier.
A method for treating an IgE-mediated disease in a subject, the method comprising administering to a subject a pharmaceutical composition containing an effective amount of a compound selected from:
- a compound of formula X1—R0 (SEQ ID NO:
- 214), wherein R0 comprises SEQ ID NO:
- 4 and X1 comprises
- TT QSLKQLEERA ARNVSQVSKN LESHHGDQMA QKSQSTQISQ ELEELRAEQQ RLKSQDLELS WNLNGLQADL SSFKSQELNE RNEASDLLER LREEVTKLRM ELQVS (SEQ ID NO:
- 7), or a contiguous fragment of at least 15 amino acids of SEQ ID NO:
- 7, wherein the compound does not bind detectably to CD21,
- a compound of formula R0—X2 (SEQ ID NO:
- 215), wherein R0 comprises SEQ ID NO:
- 4 and X2 comprises SEGSAE (SEQ ID NO:
- 9), SEGSA (SEQ ID NO:
- 10), SEGS (SEQ ID NO:
- 11), SEG, SE, S, L, or —COOH , wherein the compound does not bind detectably to CD21, and
- a compound of the formula X1—R0—X2 (SEQ ID NO:
- 216), wherein R0 comprises SEQ ID NO:
- 4, X1 comprises at least 15 contiguous amino acids of TT QSLKQLEERA ARNVSQVSKN LESHHGDQMA QKSQSTQISQ ELEELRAEQQ RLKSQDLELS WNLNGLQADL SSFKSQELNE RNEASDLLER LREEVTKLRM ELQVS (SEQ ID NO:
- 7), and X2 comprises SEGSAE (SEQ ID NO:
- 9), SEGSA (SEQ ID NO:
- 10), SEGS (SEQ ID NO:
- 11), SEG, SE, S, L, or —COOH, wherein the compound does not bind detectably to CD21;
- and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.